Protagonist Therapeutics (PTGX) Stock: Buy, Sell, or Hold?
PTGX - Protagonist Therapeutics, Inc
$139.53
1.45 (1.05%)
▲
5d:
+2.18%
30d:
+0.6%
90d:
+2.51%
BUY
HIGH Confidence
Analysis Updated: Oct 22, 2026 12:00 AM ET
Earnings: Nov 05, 2026
12d
Get Alerted When PTGX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: PTGX shows strong fundamentals and good volume confirmation. Solid entry point despite fair pricing.
✅ BUY SIGNAL: PTGX shows strong fundamentals and good volume confirmation. Solid entry point despite fair pricing.
In-depth Analysis How we analyze
Valuation Analysis: PTGX is currently trading at $139.53, which is considered fair relative to its 30-day fair value range of $136.65 to $144.11. From a valuation perspective, the stock is trading at a discount (Forward PE: -1405.1) compared to its historical average (83.6). At these levels, the market is pricing in 0% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, PTGX is in a uptrend. Immediate support is located at $126.39, while resistance sits at $152.19.
Market Sentiment: PTGX scores 74/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $178.57 (+28.0%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, PTGX is in a uptrend. Immediate support is located at $126.39, while resistance sits at $152.19.
Market Sentiment: PTGX scores 74/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $178.57 (+28.0%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$136.65 -
$144.11
Company Quality Score
64/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
90.4%
All Signals
- NEUTRAL: Price in fair range
- BULLISH: Options cheap (IV 0th percentile)
- BULLISH: Strong technical setup (74/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 28.0% below Wall St target ($178.57)
- BULLISH: Market expects only 0% annual growth - appears undervalued
- BULLISH: Bottoming setup score 74/100 — corrected, stabilizing, and turning up
Trading Range Analysis
30-Day Trading Range
$136.65 -
$144.11
Current vs Trading Range
FAIR
Expected Move (7 Days)
±$7.63
(5.5%)
Support & Resistance Levels
Support Level
$126.39
Resistance Level
$152.19
Current Trend
Uptrend
Technical data as of
Oct 22, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-1405.14
Wall Street Target
$178.57
(+28.0%)
Revenue Growth (YoY)
3749.2%
Earnings Growth (YoY)
351.3%
Profit Margin
29.4%
PE vs Historical
-1405.1 vs 83.6
CHEAP
Share & Embed Analysis
Last updated: October 23, 2026 4:05 AM ET
Data refreshes hourly during market hours. Next update: 5:05 AM
Data refreshes hourly during market hours. Next update: 5:05 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is PTGX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
INSM
Insmed Inc |
STRONG BUY
24 analysts |
$197 | 52 HOLD |
|
CYTK
Cytokinetics Inc |
STRONG BUY
22 analysts |
$109 | 61 BUY |
|
MDGL
Madrigal Pharmaceuticals… |
STRONG BUY
19 analysts |
$686 | 62 BUY |
|
CRSP
Crispr Therapeutics AG |
BUY
23 analysts |
$86 | 66 BUY |
|
CGON
CG Oncology, Inc. Common… |
STRONG BUY
15 analysts |
$91 | 64 BUY |
Advanced PTGX Option Strategies
Professional options setups generated by AI based on today's PTGX price and gamma walls.
